In:
The Journal of Immunology, The American Association of Immunologists, Vol. 208, No. 1_Supplement ( 2022-05-01), p. 104.08-104.08
Abstract:
Several lines of evidence suggest that the pathobiont Porphyromonas gingivalis is involved in the development and/or progression of rheumatoid arthritis. This bacterium produces cysteine proteases, such as gingipain RgpA, endowed with the potential to induce significant inflammation in patients with periodontitis and rheumatoid arthritis. Both diseases involve chronic inflammation with the production of pro-inflammatory cytokines, connective tissue breakdown and bone erosion. Methods A 25-peptide named BR1 from Porphyromonas gingivalis was synthesized for the study. Serum samples from patients with RA, early arthritis, other rheumatic diseases, and normal controls were used in the study. A monoclonal antibody named BR2mAb was derived from BALB/c mice immunized with the 25-mer peptide was produced as the control. Anti-BR1, ACPA and RF were detected by ELISA. Results Anti-BR1 were detected in 56.0% (59/106) of RA patients and were found in 63.8% (23/36) of RA patients without both RF and/or ACPA. The serological positive rates with the two tests of RF and ACPA and with the three tests of anti-BR1, RF, and ACPA were 66% and 84.2%, respectively. Anti-BR1 were detected in 60.0% (9/15) of patients with early arthritis, but neither RF nor ACPA was detected in this group of patients. The sensitivity and specificity for RA were 60.1% and 95%, respectively. The BR2 mAb reacted to Porphyromonas gingivalis as well. Conclusions A specific 25-mer peptide from the cysteine protease of P. gingivalis is the epitope for humoral immune response in rheumatoid arthritis. The anti-25-mer peptide antibody test is an excellent new test for the diagnosis of patients with RA and early arthritis. This study was supported by grants from the Ministry of Science and Technology, Taiwan (MOST-104-2314-B-039-045, MOST-105-2911-I-039-504, MOST-105-2314-B-039-047, MOST-106-2911-I-039-501, MOST-107-2314-B-039-050, MOST-108-2314-B-039-019), and from China Medical University Hospital (DMR-106-188, DMR-108-183, DMR-109-206).
Type of Medium:
Online Resource
ISSN:
0022-1767
,
1550-6606
DOI:
10.4049/jimmunol.208.Supp.104.08
Language:
English
Publisher:
The American Association of Immunologists
Publication Date:
2022
detail.hit.zdb_id:
1475085-5
Bookmarklink
